DRG Epidemiology’s coverage of herpes zoster (HZ) comprises epidemiological estimates of key patient populations in the mature pharmaceutical markets. We report the incidence of HZ for each…
Multiple myeloma remains an incurable hematological malignancy despite the availability of several treatments. Resistance to therapy is the primary challenge associated with the disease’s relapse…
The current treatment armamentarium for non-small-cell lung cancer (NSCLC) is dominated by biomarker-driven therapies and immune checkpoint inhibitors. Therapeutic options in this indication have…
Clarivate Epidemiology's coverage of soft tissue sarcoma comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France…
Multiple myeloma remains an incurable hematological malignancy despite the availability of several treatments. Resistance to therapy is the primary challenge associated with the disease’s relapse…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatment options exist, physicians, patients, and healthcare systems are concerned about their limitations. Delivery…
Epidemiology’s coverage of dry eye disease (DED) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany,…
Clarivate Epidemiology’s coverage of acute heart failure (AHF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the hospitalization rate of AHF…
Chronic low back pain (CLBP), defined as continuous low back pain lasting for at least three months, is one of the largest segments of the chronic pain therapy market. Prescription treatment…
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as well as…
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as well as…
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of migraine for each country, as well as…
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of migraine for each country, as well as…
DRG Epidemiology’s coverage of migraine comprises epidemiological estimates of key patient populations in 45 countries. We report the prevalence of migraine for each country, as well as…
Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key migraine patient populations covering 171 countries and more than 99…